Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 535

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 535
---
 drug candidates. These drug candidates are being developed to treat a wide spectrum of diseases, including solid tumors, hematological malignancies and immunological diseases which we believe may address unmet medical needs and represent large commercial opportunities. Our success in research and development has led to partnerships with leading global pharmaceutical companies, including AstraZeneca, Eli Lilly and Takeda. We and our collaboration partners have invested approximately $2.1 billion in our Oncology/Immunology operations as of December 31, 2024, with almost all of these funds used for research and development expenses for the development of our drug candidates. Net loss attributable to our company from our Oncology/Immunology operations was $385.4 million for the year ended December 31, 2022, net income attributable to our company from our Oncology/Immunology operations was $51.2 million for the year ended December 31, 2023 and net loss attributable to our company from our Oncology/Immunology operations was $24.6 million for the year ended December 31, 2024.
In addition, we have built large-scale and profitable drug marketing and distribution capabilities through subsidiaries and a joint venture in our Other Ventures, which primarily manufacture, market and distribute prescription drugs and healthcare products in China. Net income attributable to our company generated from our Other Ventures operations was $54.6 million, $50.3 million and $47.7 million for the years ended December 31, 2022, 2023 and 2024, respectively. In addition to helping fund our Oncology/Immunology operations, we utilize the know-how from our Other Ventures to support the commercialization of our internally developed Oncology/Immunology products in China.
Our consolidated revenue was $426.4 million, $838.0 million and $630.2 million for the years ended December 31, 2022, 2023 and 2024, respectively. Net loss attributable to our company was $360.8 million for the years ended December 31, 2022 and net income attributable to our company was $100.8 million and $37.7 million for the years ended December 31, 2023 and 2024, respectively.

We continue to deliver on our strategy to create value, prioritize our portfolio and bring innovative medicines to patients globally. To focus on our core business of discovering, developing and commercializing novel therapies for the treatment of cancers and immunological diseases including the advancement